Streetbeat News

Equity Actions

BMY

Bristol Myers Squibb (NYSE:BMY) has announced Christopher Boerner as their new Chair of the Board of Directors and CEO. Boerner will take over as Chair in April 2024 and as CEO from November 1. He succeeds Giovanni Caforio, who is retiring after 23 years of service. The company recently reported its Q3 2023 financial results, with revenues of $11 billion and GAAP EPS of $0.93. However, U.S. revenues fell 4% due to lower sales of Revlimid.

Portfolio Pulse from Benzinga Neuro

November 01, 2023 | 1:09 am

FLJ

FLJ Group has announced the sale of its long-term apartment rental business. The company has entered into an equity transfer agreement to sell all of its equity interest in its wholly-owned subsidiary Haoju (Shanghai) Artificial Intelligence Technology Co., Ltd. to Wangxiancai Limited.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 10:03 pm

INCR

InterCure has won an arbitration proceeding against Cannolam. As a result, InterCure now holds 100% of the shares in Cannolam. The amount owed will be determined and paid as part of a full separation process.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:54 pm

UNFI

United Natural Foods, Inc. (NYSE:UNFI) has appointed Andre Persaud as President and Chief Executive Officer of Retail, effective November 6, 2023. Persaud brings nearly 30 years of retail experience and a track record of success. He will lead the company's two retail banners, CUB and Shoppers Food Warehouse, and report to Sandy Douglas, UNFI's CEO and President. Persaud has held senior leadership roles with large food and pharmacy operations, including Rite Aid, Wakefern Foods/ShopRite, Shopko Stores, Burlington, Loblaw Companies, Shoppers Drug Mart, and Wal-Mart Canada.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:51 pm

SEDA

SDCL EDGE Acquisition Corporation has announced that its shareholders have approved the extension of the deadline to complete a business combination to March 2, 2024. The company has also maintained 65.9% of the capital in its trust account, with 13,177,933 Class A Ordinary Shares remaining in float. The company has entered into a non-binding letter of intent with Magnet Joint Venture GmbH, KME SE, and The Paragon Fund III GmbH & Co. for a proposed business combination relating to Cunova GmbH and certain assets of KME comprising KME's Aerospace Business.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:50 pm

BXC

BlueLinx Holdings Inc. (NYSE:BXC) has announced a new share repurchase authorization of $100 million. The repurchase will be funded through a combination of cash on hand and cash flow from operations. The decision to repurchase shares will depend on various factors including the company's capital needs, the market price of the stock, and general market conditions.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:48 pm

RBB

RBB Bancorp has announced the appointment of Mina Rizkalla as SVP/Sr. BSA Officer and Deputy Chief Risk Officer. Rizkalla will head the Bank's Bank Secrecy Act department and oversee the Bank's Anti-Money Laundering/Countering the Financing of Terrorism compliance program. The company also announced that it will resume its share repurchase program, with approximately 433,000 shares remaining available for repurchase.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:46 pm

SELB

Selecta Biosciences (NASDAQ:SELB) has announced an agreement to transition the manufacturing and development rights and remaining clinical operations of ImmTOR for SEL-212 to its partner, Swedish Orphan Biovitrum AB (Sobi). As of November 6, 2023, Sobi will assume responsibility for the manufacturing and commercial supply of ImmTOR for SEL-212. Selecta believes this transition will streamline its organization and optimize the value of its SEL-212 royalty stream for stockholders. Selecta is eligible to receive up to $615.0 million in remaining regulatory and commercial milestone payments and tiered double-digit royalties on net sales of SEL-212.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:42 pm

XHR

Xenia Hotels & Resorts has updated its full year 2023 outlook, forecasting an adjusted FFO per diluted share of $1.48-$1.55. The guidance reflects macroeconomic uncertainty and does not account for any unanticipated impacts to the business or operations. It also assumes no additional acquisitions, dispositions, equity issuances, or share and/or senior note repurchases. The company expects a negative impact of 250 basis points to Same-Property (32 Hotel) RevPAR Change due to renovation disruption.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:39 pm

PSTV

Plus Therapeutics reported its Q3 financial results and announced a share repurchase program, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:25 pm